Last reviewed · How we verify
ARQ-151 cream 0.15%
ARQ-151 is a selective phosphodiesterase 4 (PDE4) inhibitor that modulates inflammatory responses.
ARQ-151 is a selective phosphodiesterase 4 (PDE4) inhibitor that modulates inflammatory responses. Used for Plaque psoriasis.
At a glance
| Generic name | ARQ-151 cream 0.15% |
|---|---|
| Sponsor | Arcutis Biotherapeutics, Inc. |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 1 |
Mechanism of action
By inhibiting PDE4, ARQ-151 increases intracellular cAMP levels, which leads to reduced production of pro-inflammatory cytokines and mediators, thereby alleviating inflammation and associated symptoms.
Approved indications
- Plaque psoriasis
Common side effects
- Application site irritation
Key clinical trials
- Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (PHASE3)
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (PHASE3)
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) (PHASE3)
- Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema (PHASE1)
- Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis (PHASE2)
- The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis (PHASE2)
- Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARQ-151 cream 0.15% CI brief — competitive landscape report
- ARQ-151 cream 0.15% updates RSS · CI watch RSS
- Arcutis Biotherapeutics, Inc. portfolio CI